Rx License-Rx

PIA01-02

Novel Class of Anthelmintic Compounds and Proprietary Screening Method for Anthelmintic Discovery

Novel anthelmintics with differentiated mechanisms of actions and therapeutic efficacy across multiple developmental stages

Intelligence Memo

Owner: New York University

Core category: Research Tools

Therapeutic area: Platform Technology

Indication:

Modality: Small Molecule

Focus tags: Needs review

Technology tags: Small Molecule

Mechanism:

Development stage: Early / Discovery

Patent status: Needs review

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a research tool or translational platform in Platform Technology. The near-term value is helping pharma, CROs, or labs make better experimental or patient-selection decisions. The current package appears to be early / discovery and is associated with New York University. The practical first use case is the narrowest patient segment where the mechanism can create a measurable signal quickly. Public description: Novel anthelmintics with differentiated mechanisms of actions and therapeutic efficacy across multiple developmental stages

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Indication narrowing plus an outsourced translational evidence package

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

First indication is not obvious: A broad use case can waste capital. The license needs one narrow patient segment or buyer problem before development starts.

IP quality is not yet clear: Patent scope, remaining term, ownership, sponsored-research rights, and freedom to operate need counsel review before deal commitment.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Roche Diagnostics — Companion diagnostic and translational biomarker fit. Thermo Fisher — Research-tool commercialization and pharma services channels. Illumina / Tempus — Data, sequencing, and clinical decision-support adjacency.

Development Strategy to Increase PoS

First indication: the narrowest patient segment where the mechanism can create a measurable signal quickly

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence package Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package

Best next experiment: Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.